Combining glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) in patients with type 2 diabetes mellitus (T2DM)

Due to their cardiovascular protective effect, glucagon-like peptide-1 receptor agonists (GLP-1RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) represent breakthrough therapies for type 2 diabetes mellitus (T2DM). In this review article, we discuss the mechanistic and clinical synergies...

Descripción completa

Detalles Bibliográficos
Autores principales: Gourdy, Pierre, Darmon, Patrice, Dievart, François, Halimi, Jean-Michel, Guerci, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067319/
https://www.ncbi.nlm.nih.gov/pubmed/37005640
http://dx.doi.org/10.1186/s12933-023-01798-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10067319/
https://www.ncbi.nlm.nih.gov/pubmed/37005640
http://dx.doi.org/10.1186/s12933-023-01798-4

Ejemplares similares